10x Genomics, Inc. (TXG) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
10x Genomics’s revenue went from $71M in fiscal 2017 to $643M in fiscal 2025, growth of about 31.7% a year.
Net income in fiscal 2025 was -$44M, a net margin of -6.8%; the best year in this period was 2017 with -$19M.
Over the twelve months to September 30, 2026, revenue was $619M and net income -$67M.
Free cash flow was $130M in fiscal 2025 and positive in 1 of the 9 years shown.
The diluted share count rose 977% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $619M | $643M | $611M | $619M | $516M | $490M | $299M | $246M | $146M | $71M |
| Gross profit | $445M | $444M | $414M | $409M | $396M | $416M | $240M | $185M | $118M | $61M |
| Operating income | -$72M | -$61M | -$195M | -$265M | -$168M | -$52M | -$534M | -$31M | -$111M | -$18M |
| Net income | -$67M | -$44M | -$183M | -$255M | -$166M | -$58M | -$543M | -$31M | -$112M | -$19M |
| EPS (diluted) | $-0.52 | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 | $-8.40 | $-1.62 |
| R&D | $223M | $239M | $265M | $270M | $266M | $212M | $123M | $83M | $48M | $32M |
| Revenue growth | — | +5.2% | −1.3% | +19.8% | +5.3% | +64.1% | +21.5% | +68.1% | +105.8% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $100M | $136M | $7M | -$15M | -$34M | -$21M | -$218M | $35M | -$76M | -$11M |
| Capital spending | -$6M | -$6M | -$12M | -$49M | -$132M | -$101M | -$37M | -$43M | -$6M | -$4M |
| Free cash flow | $94M | $130M | -$6M | -$64M | -$165M | -$123M | -$255M | -$8M | -$83M | -$14M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | $80000 |
| Stock-based pay | $97M | $109M | $141M | $167M | $137M | $96M | $49M | $13M | $3M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $523M | $393M | $389M | $430M | $587M | $664M | $424M | $65M | $48M |
| Debt | — | $84M | $83M | $95M | $95M | $82M | $63M | $84M | $30M | — |
| Equity | — | $796M | $710M | $741M | $806M | $818M | $739M | $420M | -$220M | -$113M |
| Total assets | — | $1.0B | $919M | $965M | $1.0B | $1.0B | $929M | $606M | $124M | — |
| Shares (diluted) | 131M | 125M | 120M | 117M | 114M | 110M | 101M | 39M | 13M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 71.9% | 69.0% | 67.9% | 66.1% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating margin | -11.7% | -9.5% | -31.9% | -42.9% | -32.5% | -10.7% | -178.7% | -12.4% | -75.7% | -25.9% |
| Net margin | -10.8% | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| FCF margin | 15.2% | 20.2% | -0.9% | -10.3% | -32.0% | -25.0% | -85.2% | -3.3% | -56.5% | -20.3% |
| ROIC | — | -5.5% | -19.4% | -25.1% | -14.7% | -4.6% | -52.6% | -4.8% | — | — |
| ROE | — | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% | -73.4% | -7.4% | 51.1% | 16.7% |
Frequently asked questions
What is 10x Genomics’s annual revenue?
$643M in fiscal 2025 and $619M over the twelve months to September 30, 2026.
How much profit does 10x Genomics make?
Net income was -$44M in fiscal 2025 (net margin -6.8%).
Is 10x Genomics’s revenue growing?
Yes: revenue rose 5.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.